Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab.
Anton W LangerakMatthias RitgenValentin GoedeSandra RobrechtJasmin BahloKirsten FischerMichael SteurerMarek TrněnýStephen P MulliganUlrich J M MeyKerstin TrunzerGünter Fingerle-RowsonKathryn HumphreyStephan StilgenbauerSebastian BöttcherMonika BrüggemannMichael HallekMichael KnebaJacques J M van DongenPublished in: Blood (2018)